Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Testosterone Articles

GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN

4 May 1992

NITRATES: OLD DRUGS, BUT ONES WITH A FUTURE

20 April 1992

1991 A "SUPERB" YEAR FOR MARION MERRELL DOW

13 April 1992

OPTIMISTIC ANALYSIS OF WARNER-LAMBERT

13 April 1992

GYNEX TO MARKET DELATESTRYL

13 April 1992

NICOTINELL TTS LAUNCHED IN FRANCE

6 April 1992

NICOTINELL TTS LAUNCHED IN FRANCE

6 April 1992

ESTRAPAK FOR OSTEOPOROSIS IN UK

23 March 1992

WORLD MARKETS FOR DRUG DELIVERY

23 March 1992

RECORD 4TH QTR FROM US DRUG COMPANIES

10 February 1992

MERCK'S PROSCAR NEARING US APPROVAL

10 February 1992

ELAN'S NICOTINE PATCH

3 February 1992

ALZHEIMER'S DISEASE: US CONCERN

27 January 1992

ALZA PRODUCT PROMOTIONS

20 January 1992

ANESTHETIC PRODUCT PACT

20 January 1992

US MARKET FORECASTS FROM FROST & SULLIVAN

6 January 1992

MMD TO RESTART NICODERM SALES

6 January 1992

TREATMENT IND FOR GYNEX' OXANDRIN

6 January 1992

FTC sues Watson and Par over AndroGel deal

Showing 701-719 of 719 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS